anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a prospective randomised open label Phase III study. This study is is proposed to compare a rapid fractionation schedule of 1 week compared to a protracted schedule of 6-8 weeks for palliation for locally advanced cervical cancer. The primary objective of the study is pain relief in the experimental arm as compared to the control arm from treatment until 12 weeks from start of radiotherapy. Patients with locally advanced cervical cancer (Stage III B-IV A) deemed unsuitable for full course radical pelvic radiotherapy or chemoradiation, patients whose anticipated survival is less than 12 months will be included in the study. Patients with distant metastasis and those with retroviral disease will be excluded from the study. The patients will be randomised in one of the two groups:

Arm A : Control Arm - Long Course Palliative Radiation: Week 1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week 4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week 7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients which will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity.

Arm B: Experimental arm- Short Course Palliative radiation. Week 1: Patients will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.There is no potential direct benefit to the study participants. However the aim is to use the available information to evolve treatment in future. The variables to be estimated are pain relief, disease related symptoms relief, CTCAE Toxicity, Quality of Life,overall survival and compliance to therapy.
Children are frequently exposed to various biological trace metals, some essential for their development, while others can be potent neurotoxicants. Furthermore, the inflammatory and metabolic conditions associated with obesity may interact with and amplify the impact of metal exposure on neurodevelopment. However, few studies have assessed the potential modification effect of body mass index (BMI). As a result, we investigated the role of child BMI phenotype on the relationship between prenatal exposure to metal mixtures and temporal processing. Leveraging the PROGRESS birth cohort in Mexico City, children (N = 563) aged 6-9 years completed a Temporal Response Differentiation (TRD) task where they had to hold a lever down for 10-14 s. Blood and urinary metal (As, Pb, Cd, and Mn) measurements were collected from mothers in the 2nd and 3rd trimesters. Child BMI z-scores were dichotomized to normal (between -2 and +0.99) and high (≥1.00). Covariate-adjusted weighted quantile sum (WQS) regression models were used to estimate and examine the combined effect of metal biomarkers (i.e., blood and urine) on TRD measures. Effect modification by the child's BMI was evaluated using 2-way interaction terms. Children with a high BMI and greater exposure to the metal mixture during prenatal development exhibited significant temporal processing deficits compared to children with a normal BMI. Notably, children with increased exposure to the metal mixture and higher BMI had a decrease in the percent of tasks completed (β = -10.13; 95 % CI: -19.84, -0.42), number of average holds (β = -2.15; 95 % CI: -3.88, -0.41), longer latency (β = 0.78; 95 % CI: 0.13, 1.44), and greater variability in the standard deviation of the total hold time (β = 2.08; 95 % CI: 0.34, 3.82) compared to normal BMI children. These findings implicate that high BMI may amplify the effect of metals on children's temporal processing. Understanding the relationship between metal exposures, temporal processing, and childhood obesity can provide valuable insights for developing targeted environmental interventions.
BACKGROUND: Breast Cancer and cardiovascular diseases are amongst the two leading causes of mortality in the United States, and the two conditions are connected in part because of recognized cardiotoxicity of cancer treatments. The aim of this study is to investigate the predictors risk factors for thirty-day readmission in female breast cancer survivors presenting with acute heart failure.
METHODS: This is a retrospective cohort study of acute heart failure (AHF) hospitalization in female patients with breast cancer in 2019 using the National Readmission Database (NRD), which is the largest publicly available all-payer inpatient readmission database in the United States. Our study sample included adult female patients aged 18 years and older. The primary outcome of interest was the rate of 30- day readmission.
RESULTS: In 2019, there were 8332 total index admissions for AHF in females with breast cancer and 7776 patients were discharged alive. The mean age was 74.4 years (95% CI: 74, 74.7). The percentage of readmission at 30 days among those discharged alive was 21.8% (n = 1699). Hypertensive heart disease with chronic kidney disease accounted for the majority of readmission in AHF with breast cancer followed by sepsis, acute kidney injury, respiratory failure, pneumonia, and atrial fibrillation. Demographic factors including higher burden of comorbidities predict readmission. The total in-hospital mortality in index admission was 6.67% (n = 556) and for readmitted patients was 8.77% (n = 149). The mean length of stay for index admission was 7.5 days (95% CI: 7.25, 7.75).
CONCLUSIONS: Readmission of female breast cancer survivors presenting with AHF is common and largely be attributed to high burden of comorbidities including hypertension, and chronic kidney disease. A focus on close outpatient follow-up will be beneficial in lowering readmissions.
TF-CBT is an evidence-based therapeutic approach to improve symptoms of PTSD as well as affective or cognitive and behavioral problems. The treatment will consist of three phases that will include: Psychoeducation, Relaxation-Mindfulness, Emotional regulation skills, Cognitive coping skills, Narration and processing of trauma, Exposure / Desensitization of memories of the trauma, Self-esteem and future goals. The treatment is composed by 3 phases: 1) Phase 1: TF-CBT Coping Skills for Complex Traumas. Phase 2: Narration of trauma and processing of complicated trauma. Phase 3: Consolidation and closure of the treatment. Each case is delivered to the participants in a maximum of 3 sessions per phase.
The intervention will involve one session of maximal eccentric exercise of the knee extensor muscles (quadriceps) of the right leg. During the 24-hour period preceding the intervention, participants will be asked to refrain from any for of moderate-vigorous physical activity or exercise. Participants will perform 30 sets of 10 repetitions of maximal isokinetic eccentric knee extensions at 60 degrees/second with 1-minute of rest between each set. Before completing the exercise bout, each participant will be asked to remain in a seated position (resting) for 30-minutes and then provide a skeletal muscle biopsy using the modified Bergstrom with suction muscle biopsy technique from the vastus lateralis on the right leg. This will be done for the baseline assessment of 5 myokines including apelin, fibroblast growth factor-21, irisin, interleukin-6, and interleukin-15. Then the participants will complete the exercise bout as described above. They will then rest quietly in the laboratory for 3-hours and wait for the second skeletal muscle biopsy to be taken following this 3-hour wait.
A concentrate composition comprising: (a) at least 0.1 wt% of a surfactant compound; and (b) at least 10 wt% one or more ingredients selected from aldehydes, succinimidyl esters, chelating agents and amine salts of carboxylic acids. Most preferably, the aldehyde is 2-hydroxyoctanal; most preferably the chelating agent is either glutamic acid N,N-diacetic acid (GLDA) or diethylene triamine pentaacetic acid (DTPA). Most preferably the amine salt of a carboxylic acid is the triethanolamine salt of octanoic acid. Most preferably, the surfactant is either sodium laureth sulfate (SLES, SLS), or cocamidopropyl betaine (CAPB), or mixtures thereof. Preferably (a) and (b) together amount for, at least, 20 wt.% of the composition. Preferably, the composition is a stable emulsion. Most preferably the composition comprises all of: a surfactant, an aldehyde, a chelate and the amine salt of a carboxylic acid. Composition is claimed as being able to combat colour loss of dyed material (e.g. hair).
The invention relates to the field of veterinary medicines, in particular to a medicine for treating the pullorum disease and a preparing and detecting method and application of the medicine. The medicine comprises, by weight, 1-2 parts of the root barks of white mulberries and 1-2 parts of vernonia patula. The medicine is prepared into powder and granules. The preparing method comprises the steps that 11-times amount of water is added to dried root barks of white mulberries and dried vernonia patula for 1 hour for the first time, decocting is conducted for 1 hour, 4-times amount of water is added for the second time, decocting is conducted for 1 hour, water decoctions are combined and filtered, filter liquid is concentrated, drying is conducted, fine powder is formed through smashing, sieving and blending are conducted, and the powder is formed. According to the chromatographic condition of the medicine quality detecting method, a HypersilDs chromatographic column is adopted, the mobile phase is an acetonitrile-1% glacial acetic acid solution with the proportion of 30 to 70, the detecting wave length is 200 nm, the column temperature is 20 DEG C, the flow speed is 1.0 mL*min-1, and the sample size is 10 micro-liters. The medicine has the great advantages for treating various dampness and heat diseases, the red-white dysentery, the damp-heat dysentery and the like of birds and beasts.
The invention relates to the technical field of biology, in particular to application of a TN inhibitor in preparation of a drug for improving beta cell function and preventing and/or treating diabetes. The study of the invention found that TN is elevated in serum of both obese and diabetic patients and mice. In addition, knockout of the TN gene improves glucose tolerance in mice, while acute administration of TN supplementation exacerbates glucose intolerance in mice. TN was also found by Binding experiments to bind with high affinity to human and mouse islet tissue. TN treatment of pancreatic islet beta cells decreases the ability of beta cells to stimulate insulin secretion (GSIS) by glucose. The results demonstrate that TN is a novel adipokine, playing an important role in obesity-induced beta cell dysfunction. Thus, targeting the TN signaling pathway may be an effective therapeutic approach to improve beta cell function and treat diabetes.
Hereditary hemorrhagic telangiectasia (HHT) is characterized by systemic vascular malformations leading to recurrent bleedings and shunt formation especially in the liver, lungs and the brain. The underlying pathogenic HHT mechanism remains unclear. The wide variability in age of onset and severity of symptoms amongst patients, even within the same family, suggests several factors contribute to the complexity of this disease. Mutations in several genes of the transforming growth factor (TGF)-β superfamily pathway influence angiogenesis in patients with HHT. The genetic loss of ALK1 or ENG alone are not sufficient to induce AVMs; environmental insults that could trigger angiogenesis (e.g. wounding) are also needed. In this study it will be analyzed if hypoxic induced factors could have an influence on the disease HHT.
Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range: 200 µg mifepristone administered orally in the clinic on Day 1 then 800 μg misoprostol administered sublingually 24-48 hours later at home with a subsequent dose of 400 μg misoprostol sublingually 6 hours later if she has not expelled the pregnancy).
The invention relates to a preparation method of a wood frog spawn polysaccharide extract, and an application of the wood frog spawn polysaccharide extract in immunity enhancement. The method is characterized in that the method comprises the following steps: extracting wood frog spawn polysaccharides from wood frog spawn as a raw material through an enzymatic hydrolysis technology, filtering or centrifuging, carrying out alcohol precipitation on the above obtained filtered or centrifuged solution with anhydrous ethanol 3 times the volume of the filtered or centrifuged solution to obtain a precipitate which is the polysaccharide extract, freeze-drying or oven-drying to prepare an extract or dry powder; and the obtained ethanol liquid is recovered below 40DEG C. The wood frog spawn polysaccharides have mouse lymphocyte conversion promotion effects on in vitro mouse spleens to different degrees, a good dose-effect relationship exists, and the polysaccharide extract with the concentration of 0.001[mu]g/mL still has a strong lymphocyte conversion promotion effect. In mouse in vivo experiments, a wood frog spawn polysaccharide sample has an obvious lymphocyte conversion promotion effect. In the field of the influences on cytokines in mouse serum, the influences of the wood frog spawn polysaccharides on the outputs of TNF-alpha and IL-1beta in the serum substantially change. The wood frog spawn polysaccharide extract can be used to prepare immune medicines, and can also be used as a food additive. The extraction method and the extract solvent are not limited to that mentioned in the experiments and the embodiments.
A treatment cycle is 21 days. Treatment will be repeated until disease progression is detected by imaging studies or unacceptable toxicities are encountered. On Day 1, all patients will receive docetaxel 75 mg/m2 by intravenous (IV) infusion over 1 hour. Oral dexamethasone (16 mg, given as 8 mg twice daily) will be given on the day prior to, the day of (Day 1), and the day following docetaxel infusion (Day 2). Antiemetic prophylaxis will be administered according to institutional guideline for docetaxel. Institutional guideline/practice should be followed in the event of infusion/hypersensitivity reaction. Diphenhydramine and dexamethasone infusion may be administered in the event of infusion reaction.
The present invention relates to molecues which modify the binding between AKAP 18.delta. and phosphodiesterase 4D or AKAP 18.delta. and phospholamban and their use in altering PKA type II-mediated, activation of SERCA2 in a cell, for example to alleviate cardiovascular disease. Preferably such molecules include the motif RRASTIE. Molecules such as those which mimic binding of AKAP 18.delta. to PKA which allow enhanced phosporylation of PLB  are also provided.
Film coatings for enteric and colonic release at selected pH are provided by selecting and/or formulating a shellac of a predetermined acid number. The method includes the selection of the acid number to provide the release at the specified pH and a method of providing a shellac of a predetermined acid number by blending of shellacs of different acid numbers. In general, films that release or dissolve at or above pH 7.4 are based on the selection of shellac with an acid number below 74. Films that release or dissolve above pH 7.0 are comprised of shellac selected with an acid number below 80. Films that release or dissolve at below pH 7.0 are comprised of shellac selected to have an acid number above 80. The film coating may be modified with a water soluble resin and/or a plasticizer. Preferably the shellac will comprise 50% or more of the resin system, and is formed out of water, not alcohol.
Two double-blind, controlled clinical studies of similar design (0030, a North American study and 0027, a predominately European study) were conducted to assess the efficacy of anastrozole compared with tamoxifen as first-line therapy for hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer in postmenopausal women. A total of 1021 patients between the ages of 30 and 92 years old were randomized to receive trial treatment. Patients were randomized to receive 1 mg of anastrozole once daily or 20 mg of tamoxifen once daily. The primary endpoints for both trials were time to tumor progression, objective tumor response rate, and safety.

Demographics and other baseline characteristics, including patients who had measurable and no measurable disease, patients who were given previous adjuvant therapy, the site of metastatic disease and ethnic origin were similar for the two treatment groups for both trials. The following table summarizes the hormone receptor status at entry for all randomized patients in trials 0030 and 0027.

For the primary endpoints, trial 0030 showed that anastrozole had a statistically significant advantage over tamoxifen (p=0.006) for time to tumor progression; objective tumor response rates were similar for anastrozole and tamoxifen. Trial 0027 showed that anastrozole and tamoxifen had similar objective tumor response rates and time to tumor progression (see Table 12 and FiguresError! Hyperlink reference not valid. and Error! Hyperlink reference not valid.) 

Table 12 below summarizes the results of trial 0030 and trial 0027 for the primary efficacy endpoints.

Figure 5 — Kaplan-Meier probability of time to disease progression for all randomized patients (intent to- treat) in Trial 0030

Figure 6 — Kaplan-Meier probability of time to progression for all randomized patients (intent-to-treat) in Trial 0027

Results from the secondary endpoints were supportive of the results of the primary efficacy endpoints. There were too few deaths occurring across treatment groups of both trials to draw conclusions on overall survival differences.
A purified antigen having a molecular weight of about 64 to 66 kDa as determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis. Purified endometrial proteins, free of albumin and having molecular weights of about 64 kDa and isoelectric focusing points of 3.5, 4.0, 6.0, 6.5 and 8.0 are provided. A purified endometrial protein, free of albumin and having molecular weight of 94-97 kDa and iseolectric focusing point of 3.5 is also provided. The presence of antigen composition or endometriosis-associated endometrial protein is a marker for endometriosis in a subject. A purified monoclonal antibody specifically reactive with the antigen is also provided. A method of diagnosing endometriosis in a subject is also provided. The method comprises the steps of: (a) contacting an antibody-containing sample from the subject with the antigen composition or purified endometrial proteins of the invention; and (b) detecting the reaction of the antigen with an antibody from the sample, the reaction indicating endometriosis in the subject. Having provided an endometriosis associated antigen and monoclonal antibody, a method of diagnosing endometriosis in a subject, using the MAb is also provided.
Assessing minimal residual disease (MRD) in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) is essential for adjusting therapeutic strategies and predicting relapse. Quantitative polymerase chain reaction (qPCR) is the gold standard for MRD. Alternatively, flow cytometry is a quicker and cost-effective method that typically uses leukaemia-associated immunophenotype (LAIP) or different-from-normal (DFN) approaches for MRD assessment. This study describes an optimized 12-colour flow cytometry antibody panel designed for BCP-ALL diagnosis and MRD monitoring in a single tube. This method robustly differentiated hematogones and BCP-ALL cells using two specific markers: CD43 and CD81. These and other markers (e.g. CD73, CD66c and CD49f) enhanced the specificity of BCP-ALL cell detection. This innovative approach, based on a dual DFN/LAIP strategy with a principal component analysis method, can be used for all patients and enables MRD analysis even in the absence of a diagnostic sample. The robustness of our method for MRD monitoring was confirmed by the strong correlation (r = 0.87) with the qPCR results. Moreover, it simplifies and accelerates the preanalytical process through the use of a stain/lysis/wash method within a single tube (<2 h). Our flow cytometry-based methodology improves the BCP-ALL diagnosis efficiency and MRD management, offering a complementary method with considerable benefits for clinical laboratories.
A method of promoting increased cellular hydration in a multicellular organism that is capable of intracellular water permeation includes the step of causing the multicellular organism to ingest an aqueous solution that contains an amount of a carbohydrate clathrate component. There is also a step of enhancing the intracellular permeation. The multicellular organism contains aquaporins, and the causing step involves interaction of the composition with the aquaporins. The cellular hydration promoted and caused by the method is corroborated by a test that uses human-aquaporin-expressed frog oocytes. The test uses single cell  Xenopus laevis  frog oocytes having expressed human aquaporin AGP1 water channels. There is also a beverage composition that increases lifespan in the multicellular organism, and a beverage composition that promotes cellular hydration when ingested by a multicellular organism.
The control group will receive the same amount of training under neutral gradient surface(0%).The program will be 8 weeks while in each week there will be two exercise sessions and a total of 16 sessions. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. Training intensity will be 70%-80% out of maximal heart-rate.
The embodiment of the invention discloses a Haiyangzhishui cream. The Haiyangzhishui cream comprises, by mass, 16-25% of a humectant, 2-3% of an emollient, 6-10% of a skin conditioning agent, 0.3-0.5% of an antiseptic, 0.2-0.5% of a desensitizer, 0.5-1.0% of a high-molecular polymer, and the balance of a solvent. The humectant comprises seawater, Laminaria digitata extract and trehalose; the emollient is squalane; the skin conditioning agent is hydrolyzed elastin and alga extract; the antiseptic is sea salt; the desensitizer is dipotassium glycyrrhizinate; and the high-molecular polymer is ammonium acryloyldimethyl taurate. The embodiment of the invention also discloses a preparation method of the Haiyangzhishui cream. The preparation method comprises the steps of emulsifying, mixing, cooling and stirring. The Haiyangzhishui cream prepared through the method integrates respective characteristics of toner, lotion, cream and mask, can instantly becomes a liquid, and has water supplementing, damaged skin repairing and skin resistibility and ageing resistance enhancing ability.